Liver targeting gene delivery nano-carrier as well as preparation method and application thereof
Through arginine-modified galactated chitosan nanoparticle carrier, the problem of low membrane penetration efficiency of galactated chitosan-based liver targeted drug delivery system is solved, and efficient liver targeted delivery of miR-223 is achieved and Effects on treatment of acute liver injury.
Patent Information
- Application Number
- CN202410979225.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-22
- Publication Date
- 2024-11-26
AI Technical Summary
The existing galactated chitosan-based liver targeted drug delivery system has low membrane penetration efficiency, resulting in uneven distribution of drugs and poor stability in the body.
Arginine-modified galactosynon nanoparticles are used as carriers to bind to miR-223 small molecules and specifically bind to ASGPR on the surface of hepatocytes by using electrostatic attraction to improve the membrane penetration efficiency and bioavailability of the drug.
The membrane penetration efficiency and bioavailability of miR-223 were significantly improved, liver targeting and therapeutic effects on LPS-induced acute liver injury, and enhanced drug stability and liver-specific distribution.
Smart Images

Figure CN119015436A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of medical materials, and particularly relates to a method for preparing liver-targeted nanoparticles by using arginine-modified galactosylated chitosan as a carrier material and miR-223 small molecules as a model drug. Background Art
[0002] Nano drug delivery system is one of the hot topics in targeted therapy research in recent years. After the drug is made into nanoparticles, it can be delivered to the target cells in a targeted manner, change the distribution of the drug in the body, adjust the speed and dosage of drug release, and improve stability.
[0003] MicroRNA is a class of endogenous, single-stranded, non-coding small RNA molecules consisting of approximately 19-25 nucleotides. miR-223 is expressed at the highest level in neutrophils and is considered to be a neutrophil-specific miRNA, playing a key role in attenuating neutrophil maturation and activation. In the liver, miR-223 plays an important role in maintaining cholesterol homeostasis, hepatocyte apoptosis, lipolysis, cell proliferation, etc. by negatively regulating target genes. Since miRNA itself can be rapidly degraded by RNase (RNase) in vivo and in vitro, it is highly unstable. In addition, negatively charged miRNAs can also interfere with their interaction with cell membranes, resulting in low cellular uptake efficiency.
[0004] As a small branch of the targeted drug delivery system, the liver-targeted drug delivery system (HTDDS) can effectively deliver drugs to liver lesions, improve the therapeutic index, reduce drug uptake by other normal organs, and reduce adverse reactions. Active targeting mainly includes liver targeting mediated by Asialoglycoprotein receptor (ASGPR), mediated by mannose receptor, and bile acid as a carrier, depending on the different hepatocyte receptors. ASGPR, also known as galactose receptor, is a type of efficient endosome unique to mammalian liver parenchymal cells. It can specifically recognize the galactosyl residues at the end of oligosaccharides or oligosaccharide proteins and bind tightly to them.
[0005] Chitosan (CS) is a deacetylated product of chitin. It is widely found in crustacean exoskeletons, higher plant cell walls, fungi and other cell membranes. It is the only positively charged edible fiber in nature. The chemical formula of chitosan is (C6H 11NO4)n, having the structure shown in formula (I). Chitosan nanoparticles are an ideal non-viral carrier with good biocompatibility and degradability, low immunogenicity, low toxicity, good safety, bioadhesion, sustained release and controlled release, no gene size restrictions, easy assembly, modification, easy mass production, and convenient preparation. Chitosan is positively charged under acidic conditions and easily forms nanoscale complexes with negatively charged DNA, siRNA, miRNA, etc. through electrostatic attraction. It is easy to adsorb and bind to cell membranes and then be engulfed by cells. At the same time, CS has many reaction sites, which is convenient for preparing a variety of derivatives, laying the foundation for its application in the field of biomedicine. Galactosylated chitosan (GC) is a derivative prepared by modifying the surface of chitosan with galactosyl groups. It has the structure shown in formula (II). It is a galactose ligand that can recognize and specifically bind to ASGPR on the surface of hepatocytes and enter hepatocytes by internalization, achieving the purpose of liver-targeted delivery. However, the liver-targeted drug delivery system based on galactosylated chitosan still has the problem of low membrane penetration efficiency.
[0006]
[0007] Cell-penetrating peptides (CPPs) belong to a class of naturally occurring polypeptides, also known as protein transduction domains (PTDs) or membrane transporters (MTPs). They are a class of short peptides composed of about 5-30 amino acids that carry macromolecules into cells. They have cell penetrating effects and provide a possible solution to the problem of low membrane penetration efficiency of liver-targeted drug delivery systems based on galactosylated chitosan. Summary of the invention
[0008] In order to solve the problem of low transmembrane efficiency in the liver-targeted drug delivery system based on galactosylated chitosan, the present invention proposes a scheme of loading miR-223 small molecules with arginine-modified galactosylated chitosan (GCA) nanoparticles. Arginine-modified galactosylated chitosan has a structure shown in formula (III), which can simultaneously have the advantages of targeting and carrying complex and different types of molecules, and higher transmembrane efficiency. Positively charged chitosan easily forms a nanoscale complex with negatively charged miRNA through electrostatic attraction. The modified galactose on chitosan specifically binds to the ASGPR on the surface of hepatocytes to target the liver, and arginine is added to improve the transmembrane efficiency of miR-223.
[0009]
[0010] The technical solution adopted by the present invention is as follows:
[0011] The present invention provides a liver-targeted gene delivery nanocarrier, wherein the carrier is arginine-modified galactosylated chitosan nanoparticles, and the average particle size of the nanoparticles is 100 nm; the arginine-modified galactosylated chitosan nanoparticles are obtained by cross-linking reaction between arginine-modified galactosylated chitosan and a cross-linking agent; the molecular formula of the arginine-modified galactosylated chitosan is shown in formula (III).
[0012] The preparation method of the liver-targeted gene delivery nanocarrier comprises the following steps:
[0013] 1) Dissolve 1 g of galactosylated chitosan and 2 g of arginine in 100 mL and 25 mL of morpholineethanesulfonic acid buffer, respectively, mix the two solutions and add 2 g of 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) and 1.5 g of N-hydroxysuccinimide (NHS), stir and dissolve with a magnetic stirrer, adjust the solution pH to 5.0, and stir at room temperature in the dark for 8 h;
[0014] 2) pouring the fully mixed solution into a dialysis membrane, dialyzing in deionized water for 4 days to remove the organic solvent and unreacted monomers, and freeze-drying to obtain arginine-modified galactosylated chitosan;
[0015] 3) dissolving arginine-modified galactosylated chitosan and sodium tripolyphosphate in deionized water treated with diethyl pyrocarbonate (DEPC), respectively, so that the content of arginine-modified galactosylated chitosan is 4-6 mg / mL and the content of sodium tripolyphosphate is 1 mg / mL;
[0016] 4) 1 mL of cross-linking agent sodium tripolyphosphate solution was added dropwise to 1 mL of arginine-modified galactosylated chitosan solution, and the mixture was stirred vigorously with a magnetic stirrer and allowed to stand for 30 minutes to obtain arginine-modified galactosylated chitosan nanoparticles; namely, the liver-targeted gene delivery nanocarrier.
[0017] Preferably, the dialysis membrane in step 2) has a MWCO of 8 kDa.
[0018] Preferably, the content of arginine-modified galactosylated chitosan in step 3) is 5 mg / mL.
[0019] Preferably, the preparation steps of galactosyl chitosan in step 1) are:
[0020] 1) Dissolve 1 g lactobionic acid, 2 g 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) and 1.5 g N-hydroxysuccinimide (NHS) in 25 mL morpholineethanesulfonic acid buffer and stir at room temperature for 2 h;
[0021] 2) Dissolve 1 g of chitosan in 100 mL of morpholineethanesulfonic acid buffer, mix the two solutions and stir at room temperature for 48 h;
[0022] 3) The mixed solution was loaded into a dialysis membrane, dialyzed in deionized water for 4 days and freeze-dried to obtain galactosylated chitosan.
[0023] The present invention also provides use of the liver-targeted gene delivery nanocarrier for loading miR-223.
[0024] Among them, the specific steps of the method for loading miR-223 are:
[0025] MiR-223 was dissolved in deionized water treated with diethyl pyrocarbonate (DEPC) to obtain a 20 μM miR-223 solution, and the miR-223 solution was added dropwise to the arginine-modified galactosylated chitosan nanoparticles. The mixture was thoroughly mixed with an oscillator and allowed to stand for 1 h to obtain arginine-modified galactosylated chitosan loaded miR-223 nanoparticles.
[0026] Preferably, the mass ratio of the added miR-223 to the arginine-modified galactosylated chitosan is 1:5.
[0027] Beneficial effects of the present invention:
[0028] The present invention provides a method for preparing liver-targeted nanoparticles by using an ion crosslinking method, using arginine-modified galactosylated chitosan as a carrier material and miR-223 small molecules as a model drug.
[0029] The arginine-modified galactosylated chitosan loaded miR-223 nanoparticles (GCA-miR-223) obtained by the method of the present invention modify chitosan, and modify galactose to make it liver-targeted and significantly improve the solubility of chitosan; the modification of arginine not only improves the transmembrane efficiency of miR-223 but also increases its bioavailability. The liver targeting of GCA-miR-223 and the therapeutic effect on LPS-induced acute liver injury were evaluated through animal and cell experiments. BRIEF DESCRIPTION OF THE DRAWINGS
[0030] Figure 1 The nuclear magnetic resonance hydrogen spectrum ( 1 H-NMR) chart.
[0031] Figure 2 It is a transmission electron microscope (TEM) image of the arginine-modified galactosylated chitosan loaded miR-223 nanoparticles (GCA-miR-223) prepared by the present invention.
[0032] Figure 3 It is an in vivo organ fluorescence distribution diagram of the arginine-modified galactosylated chitosan loaded miR-223 nanoparticles (GCA-miR-223) prepared by the present invention.
[0033] Figure 4 This is a diagram showing changes in the expression of inflammatory cytokines during the treatment of LPS-induced acute liver injury by arginine-modified galactosylated chitosan loaded miR-223 nanoparticles (GCA-miR-223) prepared by the present invention. DETAILED DESCRIPTION
[0034] The technical solution of the present invention is further explained and illustrated in the form of specific embodiments below.
[0035] Example 1
[0036] 1) Dissolve 1 g lactobionic acid, 2 g 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) and 1.5 g N-hydroxysuccinimide (NHS) in 25 mL morpholineethanesulfonic acid buffer and stir at room temperature for 2 h;
[0037] 2) Dissolve 1 g of chitosan (CS) in 100 mL of morpholineethanesulfonic acid buffer, mix the two solutions and stir at room temperature for 48 h;
[0038] 3) The mixed solution was loaded into a dialysis membrane (MWCO 8 kDa), dialyzed in deionized water for 4 days and freeze-dried to obtain galactosylated chitosan (GC);
[0039] 4) Dissolve 1 g of galactosylated chitosan and 2 g of arginine in 100 mL and 25 mL of morpholineethanesulfonic acid buffer, respectively, mix the two solutions and add 2 g of 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) and 1.5 g of N-hydroxysuccinimide (NHS), stir and dissolve with a magnetic stirrer, adjust the solution pH to 5.0, and stir at room temperature in the dark for 8 h;
[0040] 5) The fully mixed solution was poured into a dialysis membrane (MWCO 8 kDa), dialyzed in deionized water for 4 days to remove the organic solvent and unreacted monomers, and freeze-dried to obtain arginine-modified galactosylated chitosan (GCA).
[0041] 6) 10 mg of arginine-modified galactosylated chitosan and 10 mg of sodium tripolyphosphate were dissolved in 2 mL and 10 mL of deionized water treated with diethyl pyrocarbonate (DEPC), respectively, so that the content of arginine-modified galactosylated chitosan was 5 mg / mL and the content of sodium tripolyphosphate was 1 mg / mL.
[0042] 7) 1 mL of cross-linking agent sodium tripolyphosphate was added dropwise to 1 mL of arginine-modified galactosylated chitosan solution, and the mixture was stirred vigorously with a magnetic stirrer and allowed to stand for 30 min to obtain arginine-modified galactosylated chitosan nanoparticles. MiR-223 was dissolved in deionized water treated with diethyl pyrocarbonate (DEPC) to obtain a 20 μM miR-223 solution;
[0043] 8) 30 μL of miR-223 solution was added to 20 μL of arginine-modified galactosylated chitosan nanoparticles, mixed thoroughly with an oscillator and allowed to stand for 1 hour to obtain arginine-modified galactosylated chitosan loaded miR-223 nanoparticles (GCA-miR-223).
[0044] Figure 1 The nuclear magnetic resonance hydrogen spectrum ( 1 H-NMR) chart. Figure 1 The δ=1.50 at position ① belongs to the H on the C4-C5 carbon of arginine, and the δ=3.09 at position ② belongs to the H on the C6 carbon of arginine, which proves that the arginine-modified galactosylated chitosan nanoparticles (GCA) were successfully prepared.
[0045] Figure 2 The transmission electron microscopy (TEM) image of the arginine-modified galactosylated chitosan loaded miR-223 nanoparticles (GCA-miR-223) prepared in the present invention. Figure 2 It can be seen that the arginine-modified galactosylated chitosan loaded miR-223 nanoparticles are evenly dispersed and have a particle size of about 100 nm.
[0046] Effect verification
[0047] Verification experiment 1: The in vivo organ fluorescence distribution experiment proved that the GCA-miR-223 prepared by the present invention has liver targeting.
[0048] miR-223 and GCA-miR-223 (miR-223 content was 20 μL and labeled with Cy3) were respectively injected into the tail vein of 6-8 week old mice weighing 18-20 g, and the fluorescence distribution of mouse organs at different time points was observed. Figure 3The fluorescence distribution of mouse organs at different time points is shown. In the miR-223 group, each organ showed a large amount of fluorescence signals at 0.5h, and then the fluorescence intensity decreased significantly, indicating that free Cy3-miR-223 can be quickly cleared; while in the GCA-miR-223 group, only the fluorescence signal appeared in the liver and was gradually released, reaching a peak at 24h and then gradually decreasing. These results confirm that GCA-miR-223 nanoparticles have high liver specificity and long-term accumulation in the liver.
[0049] Verification experiment 2: The therapeutic effect of GCA-miR-223 prepared by the present invention on LPS-induced acute liver injury was demonstrated by in vitro cell detection of inflammatory cytokine expression experiment.
[0050] HepG2 cells were plated in 6-well plates and cultured for 24 hours. Cell transfection was performed when the cell density reached 60%-70%. The final concentration of transfected NC mimic and miR-223 was 100nM. After 8 hours of cell transfection, the culture medium was replaced with complete culture medium and cultured for 24 hours. 40μL LPS (concentration of 50ng / μL) was added to each well of cells. After 24 hours of stimulation, the cells were collected and RNA of each group of cells was extracted to determine the expression changes of pro-inflammatory cytokines such as IL-6 and TNF-α. Figure 4 It can be seen that the mRNA expression levels of IL-6 and TNF-α in the GCA-miR-223 group were more significantly downregulated compared with those in other groups, indicating that GCA-miR-223 nanoparticles can significantly improve LPS-induced acute liver injury.
Claims
1. A liver-targeted gene delivery nanocarrier, characterized in that: The carrier is arginine-modified galactosyl chitosan nanoparticles, and the average particle size of the nanoparticles is 100 nm; the arginine-modified galactosyl chitosan nanoparticles are obtained by cross-linking reaction between arginine-modified galactosyl chitosan and a cross-linking agent; the molecular formula of the arginine-modified galactosyl chitosan is:
2. A method for preparing a liver-targeted gene delivery nanocarrier as claimed in claim 1, characterized in that: The preparation steps are as follows: 1) Dissolve 1 g of galactosylated chitosan and 2 g of arginine in 100 mL and 25 mL of morpholineethanesulfonic acid buffer, respectively, mix the two solutions and add 2 g of 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride and 1.5 g of N-hydroxysuccinimide, stir and dissolve with a magnetic stirrer, adjust the pH of the solution to 5.0, and stir at room temperature in the dark for 8 h; 2) pouring the fully mixed solution into a dialysis membrane, dialyzing in deionized water for 4 days to remove the organic solvent and unreacted monomers, and freeze-drying to obtain arginine-modified galactosylated chitosan; 3) dissolving arginine-modified galactosylated chitosan and sodium tripolyphosphate in deionized water treated with diethyl pyrocarbonate, respectively, so that the content of arginine-modified galactosylated chitosan is 4-6 mg / mL and the content of sodium tripolyphosphate is 1 mg / mL; 4) 1 mL of cross-linking agent sodium tripolyphosphate solution was added dropwise to 1 mL of arginine-modified galactosylated chitosan solution, and the mixture was stirred vigorously with a magnetic stirrer and allowed to stand for 30 minutes to obtain arginine-modified galactosylated chitosan nanoparticles; namely, the liver-targeted gene delivery nanocarrier.
3. The preparation method according to claim 2, characterized in that: In step 2), the dialysis membrane has a MWCO of 8 kDa.
4. The preparation method according to claim 2, characterized in that: The content of arginine-modified galactosylated chitosan in step 3) is 5 mg / mL.
5. The preparation method according to claim 2, characterized in that: The preparation steps of galactosyl chitosan in step 1) are: 1) Dissolve 1 g lactobionic acid, 2 g 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride and 1.5 g N-hydroxysuccinimide in 25 mL morpholineethanesulfonic acid buffer and stir at room temperature for 2 h; 2) Dissolve 1 g of chitosan in 100 mL of morpholineethanesulfonic acid buffer, mix the two solutions and stir at room temperature for 48 h; 3) The mixed solution was loaded into a dialysis membrane, dialyzed in deionized water for 4 days and freeze-dried to obtain galactosylated chitosan.
6. Use of the liver-targeted gene delivery nanocarrier as claimed in claim 1 for loading miR-223.
7. The use according to claim 6, characterized in that MiR-223 was dissolved in deionized water treated with diethyl pyrocarbonate to obtain a 20 μM miR-223 solution, and the miR-223 solution was added dropwise to the arginine-modified galactosylated chitosan nanoparticles. The mixture was thoroughly mixed with an oscillator and allowed to stand for 1 h to obtain arginine-modified galactosylated chitosan loaded miR-223 nanoparticles.
8. The use according to claim 7, characterized in that The mass ratio of added miR-223 to arginine-modified galactosylated chitosan was 1:5.
Citation Information
Patent Citations
Application of N-arginine chitosan as percutaneous sorbefacient
CN101780281A
Triptolide chitosan nanopaticles and preparation method thereof
CN105434370A
Chitosan-N-arginine nanoparticles, and preparation method and application thereof
CN115252640A
